Emcure Partners with Roche to Boost Kidney Care Access in India

Emcure Pharmaceuticals has entered into a distribution deal with Roche for the company in the select brands of nephrology and transplant medicine in India.

The new collaboration, which will be effective on April 1, 2026, will be the decisive step in improving access to life-saving treatments for patients who treat chronic kidney disease (CKD), anemia, and organ transplants nationwide.

The contract also contains some of the world-renowned products of Roche, like CellCept, an immunosuppressant, which has been serving to uphold organ transplants all over the globe since it was introduced in 1995.

Also Read: Unlocking India's Innovation Potential in Pharma

Besides that, the two successful anti-anemia drugs against CKD, Mircera and Neorecormon, can now serve a wider range of patients. It is important to mention that Mircera possesses a long-acting ESA formula, which can be dosed every 2-4 weeks, and hence it will be more convenient for patients.

Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, also pointed out that this partnership has been a match to the desires of Emcure to enhance the care of renal and anemia. He emphasized that the innovations of Roche will strengthen the current line of Emcure in an attempt to increase the accessibility of life-saving medicines.

Through this collaboration, the two companies are going to make a significant contribution to enhancing patient outcomes and assist the healthcare providers in providing optimal care throughout India.

The agreement is a revolutionary move in the health care system of the Indian population because it is set to gain access to the necessary treatment in the field of nephrology and transplant care and enhance the lives of millions of patients with CKD and other associated issues.